Integral

Integrilin: an effective treatment for acute coronary syndrome

Integrilin, also known by its international name eptifibatide, is a pharmacological drug used in the treatment of acute coronary syndrome (ACS). ACS includes unstable angina and non-Q wave myocardial infarction. Integrilin belongs to the pharmaceutical group of antiplatelet agents and is produced by Schering-Plough in Belgium.

Integrilin is available in the form of an injection solution with two different concentrations: 2 mg/ml and 0.75 mg/ml. The active ingredient of the drug is eptifibatide.

The use of Integrilin is recommended in the acute phase of coronary syndrome in order to prevent thrombotic occlusion of the affected artery and acute ischemic complications such as death and recurrent myocardial infarction. In addition, it is used during percutaneous transluminal coronary angioplasty (PTCA).

Despite its effectiveness, Integrilin has some contraindications and limitations for use. Contraindications include hypersensitivity to the drug, a history of bleeding diathesis or severe pathological bleeding in the previous 30 days, severe arterial hypertension, "major" surgery within the previous 6 weeks, stroke in the previous 30 days or a history of hemorrhagic stroke, current or planned use of another IIb/IIIa receptor inhibitor for parenteral administration, as well as dependence on hemodialysis due to renal failure.

Pregnant women and nursing mothers should use Integrilin only in cases where the expected benefit of therapy outweighs the potential risk to the fetus or infant. When using the drug during treatment, it is necessary to stop breastfeeding, since it is unknown whether eptifibatide passes into breast milk.

When using Integrilin, you should be careful when combined with other drugs that affect the hemostatic system. Concomitant use with streptokinase may increase the risk of bleeding, and use with low molecular weight heparin is not recommended due to the lack of sufficient experience with this combination. You should also avoid co-administration of Integrilin with anticoagulants, antiplatelet agents and non-steroidal anti-inflammatory drugs, as this may increase the risk of bleeding.

It is important to note that Integrilin should be used under the supervision of a physician with expertise in cardiology or critical care and in a specialized clinical setting, such as a hospital with catheter laboratories and surgical access.

Side effects of Integrilin may include bleeding, thrombocytopenia, anemia, injection site reactions, and other allergic reactions. If serious side effects occur, you should consult your doctor immediately.

In conclusion, Integrilin (eptifibatide) is an effective drug used in the treatment of acute coronary syndrome. It helps prevent thrombotic occlusion of the affected artery and reduce the risk of acute ischemic complications. However, its use requires caution and medical supervision due to possible contraindications and side effects.